NAMS
Neutral signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
NewAmsterdam Pharma Company N.V.
- Nom
- NewAmsterdam Pharma Company N.V.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.3B
- Employés
- 100
- PDG
- Michael Harvey Davidson Facp.
- Site web
- https://www.newamsterdampharma.com
- Marché
- ABOSAMLXATHEBIOACRVODNLI
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 10 000 titres (~226 500,00 $ US) VENTE TOTALE: 1 600 titres (~40 512,00 $ US)
- Insiders
- Davidson Michael H.Smither John W
- Total bought
-
$226,500
Avg buy (VWAP, 90d window) $22.65 vs last close $20.62 (-9.0%)
- Total sold
-
$40,512
Avg sell (VWAP, 90d window) $25.32 vs last close $20.62 (-18.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-14
- Liquidity
- Liquid $34,967,041/day · 20d vol
- Last synced
-
2026-10-15 21:10:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Davidson Michael H. | Buy · P P | 10,000 | $22.65 | ≈ $226,500 | Form 4 |
| 2026-09-04 | Smither John W | Sell · S S | 1,600 | $25.32 | ≈ $40,512 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
NAMS presents a deeply conflicted profile: while insider cluster buying signals some internal confidence, the underlying fundamentals are critically weak, with persistent negative operating margins, severe cash burn…
The first sentence of the analysis written for NAMS on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 7.88 · operating margin -1003% — readings disagree
Suggested stop 18.74, 1.5 ATR under the last close(9.1% under the last close). Reward/risk to the next stored resistance is 5.88. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 99.7% | 100.0% | 100.0% | 100.0% | 0.0% | |
| Ebit Margin | -1077.8% | -530.3% | -1255.6% | -21.8% | 0.0% | |
| Ebitda Margin | -1076.9% | -530.0% | -1255.2% | -21.8% | 0.0% | |
| Operating Profit Margin | -1002.9% | -386.9% | -1298.6% | -3.5% | 0.0% | |
| Pretax Profit Margin | -905.7% | -530.3% | -1255.6% | -22.0% | 0.0% | |
| Continuous Operations Profit Margin | -905.7% | -530.3% | -1255.8% | -22.0% | 0.0% | |
| Net Profit Margin | -905.7% | -530.3% | -1255.8% | -22.0% | 0.0% | |
| Bottom Line Profit Margin | -905.7% | -530.3% | -1255.8% | -22.0% | 0.0% | |
| Current Ratio | 7.876 | 8.075 | 6.950 | 13.256 | 5.959 | |
| Quick Ratio | 7.876 | 8.075 | 6.950 | 13.256 | 5.959 | |
| Solvency Ratio | -2.371 | -2.254 | -3.013 | -0.467 | -3.677 | |
| Cash Ratio | 5.712 | 7.218 | 6.823 | 12.972 | 5.374 | |
| Price To Earnings Ratio | -20.046 | -10.039 | -5.195 | -9.160 | -2.919 | |
| Price To Earnings Growth Ratio | 0.634 | -0.526 | -0.064 | 0.142 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.634 | -0.526 | -0.064 | 0.142 | 0.000 | |
| Price To Earnings Diluted Ratio | -20.046 | -10.039 | -5.195 | -9.160 | -2.919 | |
| Price To Earnings Diluted Growth Ratio | 0.634 | -0.526 | -0.064 | 0.142 | 0.000 | |
| Price To Book Ratio | 5.872 | 3.201 | 3.182 | 0.481 | 3.056 | |
| Price To Sales Ratio | 178.337 | 53.223 | 65.133 | 2.013 | 0.000 | |
| Price To Free Cash Flow Ratio | -27.110 | -15.229 | -6.498 | 19.794 | -5.860 | |
| Price To Operating Cash Flow Ratio | -27.156 | -15.294 | -6.499 | 19.384 | -5.864 | |
| Debt To Assets Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.003 | |
| Debt To Equity Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.003 | |
| Debt To Capital Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.003 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.126 | 1.141 | 1.204 | 1.113 | 1.201 | |
| Working Capital Turnover Ratio | 0.033 | 0.087 | 0.038 | 0.413 | 0.000 | |
| Operating Cash Flow Ratio | -1.723 | -1.483 | -2.830 | 0.296 | -2.627 | |
| Operating Cash Flow Sales Ratio | -6.567 | -3.480 | -10.023 | 0.104 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.004 | 1.000 | 0.979 | 1.001 | |
| Debt Service Coverage Ratio | -1,781.801 | 0.000 | -26.016 | -77.833 | -100.655 | |
| Interest Coverage Ratio | 0.000 | 0.000 | -26.910 | -12.394 | -85.102 | |
| Short Term Operating Cash Flow Coverage Ratio | -1,086.640 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -731.599 | -353.938 | -2,353.633 | 84.643 | -158.232 | |
| Capital Expenditure Coverage Ratio | -600.744 | -235.958 | -5,884.083 | 48.258 | -1,229.667 | |
| Dividend Paid And Capex Coverage Ratio | -600.744 | -235.958 | -5,884.083 | 48.258 | -1,229.667 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -14.540 | -6.848 | -3.264 | 11.678 | -2.729 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 99.7% | ▼-0.3% | ▲19.8% |
| Ebit Margin | -1077.8% | ▼-547.6% | ▼-500.8% |
| Ebitda Margin | -1076.9% | ▼-546.9% | ▼-500.1% |
| Operating Profit Margin | -1002.9% | ▼-616.0% | ▼-464.5% |
| Pretax Profit Margin | -905.7% | ▼-375.5% | ▼-363.0% |
| Continuous Operations Profit Margin | -905.7% | ▼-375.5% | ▼-363.0% |
| Net Profit Margin | -905.7% | ▼-375.5% | ▼-363.0% |
| Bottom Line Profit Margin | -905.7% | ▼-375.5% | ▼-363.0% |
| Current Ratio | 7.877 | ▼-0.199 | ▼-0.547 |
| Quick Ratio | 7.877 | ▼-0.199 | ▼-0.547 |
| Solvency Ratio | -2.372 | ▼-0.117 | ▼-0.015 |
| Cash Ratio | 5.712 | ▼-1.506 | ▼-1.908 |
| Price To Earnings Ratio | -20.046 | ▼-10.007 | ▼-10.574 |
| Price To Earnings Growth Ratio | 0.633 | ▲1.160 | ▲0.597 |
| Forward Price To Earnings Growth Ratio | 0.633 | ▲1.160 | ▲0.597 |
| Price To Earnings Diluted Ratio | -20.046 | ▼-10.007 | ▼-10.574 |
| Price To Earnings Diluted Growth Ratio | 0.633 | ▲1.160 | ▲0.597 |
| Price To Book Ratio | 5.872 | ▲2.671 | ▲2.713 |
| Price To Sales Ratio | 178.338 | ▲125.114 | ▲118.596 |
| Price To Free Cash Flow Ratio | -27.110 | ▼-11.881 | ▼-20.130 |
| Price To Operating Cash Flow Ratio | -27.155 | ▼-11.862 | ▼-20.070 |
| Debt To Assets Ratio | 0.000 | ▼-0.000 | ▼-0.001 |
| Debt To Equity Ratio | 0.000 | ▼-0.000 | ▼-0.001 |
| Debt To Capital Ratio | 0.000 | ▼-0.000 | ▼-0.001 |
| Long Term Debt To Capital Ratio | 0.000 | ▲0.000 | ▲0.000 |
| Financial Leverage Ratio | 1.126 | ▼-0.016 | ▼-0.031 |
| Working Capital Turnover Ratio | 0.033 | ▼-0.053 | ▼-0.081 |
| Operating Cash Flow Ratio | -1.723 | ▼-0.240 | ▼-0.049 |
| Operating Cash Flow Sales Ratio | -6.567 | ▼-3.087 | ▼-2.574 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.003 | ▲0.004 |
| Debt Service Coverage Ratio | -1781.802 | ▼-1781.802 | ▼-1384.541 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲24.881 |
| Short Term Operating Cash Flow Coverage Ratio | -1086.640 | ▼-1086.640 | ▼-869.312 |
| Operating Cash Flow Coverage Ratio | -731.599 | ▼-377.661 | ▼-29.047 |
| Capital Expenditure Coverage Ratio | -600.744 | ▼-364.786 | ▲979.695 |
| Dividend Paid And Capex Coverage Ratio | -600.744 | ▼-364.786 | ▲979.695 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -14.540 | ▼-7.692 | ▼-11.399 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.01B | $2.43B | $917.7M | $206.7M | $173.1M | |
| Enterprise value | $3.52B | $1.65B | $577.3M | -$260.9M | $112.9M | |
| EV / Sales | 156.57x | 36.30x | 40.98x | -2.54x | 0.00x | |
| EV / Op. cash flow | -23.84x | -10.43x | -4.09x | -24.46x | -3.83x | |
| EV / Free cash flow | -23.80x | -10.38x | -4.09x | -24.98x | -3.82x | |
| EV / EBITDA | -14.54x | -6.85x | -3.26x | 11.68x | -2.73x | |
| Net debt / EBITDA | 2.02x | 3.19x | 1.93x | 20.93x | 1.46x | |
| Current ratio | 7.88x | 8.07x | 6.95x | 13.26x | 5.96x | |
| Income quality | 0.72x | 0.66x | 0.80x | -0.47x | 0.71x | |
| Graham net-net | $5 | $8 | $3 | $22 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 84.0% | 100.0% | 100.0% | 101.3% | 101.0% | |
| Working capital | $589.9M | $756.5M | $296.9M | $441.9M | $55.7M | |
| Invested capital | $590.9M | $757.7M | $297.2M | $442.3M | $55.9M | |
| Return on assets | -26.5% | -27.9% | -51.0% | -4.7% | -61.5% | |
| Operating ROA | -27.6% | -29.1% | -44.3% | -1.3% | -33.7% | |
| Return on tangible assets | -26.5% | -28.0% | -51.0% | -4.7% | -61.5% | |
| Return on equity | -29.8% | -31.9% | -61.4% | -5.3% | -73.8% | |
| Return on invested capital | -33.0% | -23.3% | -61.6% | -0.8% | -61.6% | |
| Return on capital employed | -33.0% | -23.3% | -61.6% | -0.8% | -61.6% | |
| Earnings yield | -5.1% | -10.0% | -19.3% | -10.9% | -24.1% | |
| Free cash flow yield | -3.7% | -6.6% | -15.4% | 5.1% | -17.1% | |
| Capex / Op. cash flow | -0.2% | -0.4% | -0.0% | 2.1% | -0.1% | |
| Capex / Depreciation | 111.8% | 594.7% | 49.0% | 2455.6% | 480.0% | |
| Capex / Sales | 1.1% | 1.5% | 0.2% | 0.2% | 0.0% | |
| SG&A / Sales | 472.4% | 154.6% | 267.1% | 19.0% | 0.0% | |
| R&D / Sales | 630.3% | 332.3% | 1131.5% | 84.5% | 0.0% | |
| Stock comp / Sales | 264.1% | 73.8% | 174.4% | 4.0% | 0.0% | |
| Intangibles / Total assets | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 376d | 171d | 49d | 0d | 0d | |
| Days payables outstanding | 55492d | 0d | 0d | 0d | 0d | |
| Operating cycle | 376d | 171d | 49d | 0d | 0d | |
| Cash conversion cycle | -55117d | 171d | 49d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+65.5%EV / Sales ▲+331.4%EV / EBITDA ▼-112.3%EV / Op. cash flow ▼-13.412Earnings yield ▲+0.049
Profitability
Return on equity ▲+0.021Return on assets ▲+0.014Return on invested capital ▼-0.098Return on capital employed ▼-0.098Operating ROA ▲+0.015Income quality ▲+0.069Tax burden +0.000
Efficiency
Days sales outstanding ▲+204.855Days payables outstanding n/aOperating cycle ▲+204.855Cash conversion cycle ▼-55287.518Capex / Sales ▼-0.004R&D / Sales ▲+2.980
Balance-sheet strength
Current ratio ▼-0.199Net debt / EBITDA ▼-1.173Working capital ▼-166582000.000Invested capital ▼-166814000.000Intangibles / Total assets -0.000
Change over 5 years
Valuation
Market cap ▲+2218.8%EV / Sales n/aEV / EBITDA ▼-432.9%EV / Op. cash flow ▼-20.016Earnings yield ▲+0.191
Profitability
Return on equity ▲+0.440Return on assets ▲+0.350Return on invested capital ▲+0.286Return on capital employed ▲+0.286Operating ROA ▲+0.060Income quality ▲+0.019Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+1.918Net debt / EBITDA ▲+0.566Working capital ▲+534193678.000Invested capital ▲+534952597.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-09-11 Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability. Insider and Institutional Ownership 89.9% of NewAmsterdam Pharma shares
- 2026-09-03 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam''s Board of Directors approved the grant of inducement share options covering an aggregate of 38,900 of NewAmsterdam''s ordinary shares to five non-executive new hires, as well as inducement share options covering 14,000 ordinary shares to Robert Gunning, the Company''s new Vice President, Controller, who serves as the Company''s principal accounting officer. The share options were granted as an inducement material to the employees'' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-02 NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.
- 2026-08-26 NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.
- 2026-08-16 NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB Handelsbanken Fonder AB lessened its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 70.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 122,400 shares of the company''s stock after selling 296,500 shares during the quarter. Handelsbanken Fonder AB owned 0.10%
- 2026-08-08 NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
- 2026-08-05 NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.
- 2026-08-05 NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48.
- 2026-08-05 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by year-end 2026 – – $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 – – Company to host investor day today at 9:00 AM ET in New York City – NAARDEN, the Netherlands and MIAMI, Aug. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended June 30, 2026 and provided a corporate update.
- 2026-07-29 NewAmsterdam Pharma to Host Investor Day on August 5, 2026 NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City.